BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8876636)

  • 1. Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications.
    Flavell DJ
    Hematol Oncol; 1996 Jun; 14(2):67-82. PubMed ID: 8876636
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeling human hematopoiesis in immunodeficient mice.
    Lapidot T; Pflumio F; Dick JE
    Lab Anim Sci; 1993 Apr; 43(2):147-50. PubMed ID: 8320962
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe combined immunodeficient mouse models of human leukemia.
    Uckun FM
    Blood; 1996 Aug; 88(4):1135-46. PubMed ID: 8695830
    [No Abstract]   [Full Text] [Related]  

  • 4. Establishment of human tumor xenografts in immunodeficient mice.
    Morton CL; Houghton PJ
    Nat Protoc; 2007; 2(2):247-50. PubMed ID: 17406581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood.
    Dialynas DP; Shao L; Billman GF; Yu J
    Stem Cells; 2001; 19(5):443-52. PubMed ID: 11553853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
    Yoshida M; Rybak RJ; Choi Y; Greenberg SJ; Barcos M; Kawata A; Matsuno F; Tsai H; Seon BK
    Cancer Res; 1997 Feb; 57(4):678-85. PubMed ID: 9044845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease.
    Dürig J; Ebeling P; Grabellus F; Sorg UR; Möllmann M; Schütt P; Göthert J; Sellmann L; Seeber S; Flasshove M; Dührsen U; Moritz T
    Cancer Res; 2007 Sep; 67(18):8653-61. PubMed ID: 17875705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment and comparison of two intraperitoneally transplanted human ovarian carcinoma models with immune reconstitution in severe combined immunodeficient mice].
    Li Y; Cui H; Chang XH; Feng J; Fu TY; Feng YJ; Wei LH
    Ai Zheng; 2004 Feb; 23(2):160-4. PubMed ID: 14960235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
    Yonou H; Yokose T; Kamijo T; Kanomata N; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2001 Mar; 61(5):2177-82. PubMed ID: 11280783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical testing of antileukemic drugs using an in vivo model of systemic disease.
    Lock RB; Liem NL; Papa RA
    Methods Mol Med; 2005; 111():323-34. PubMed ID: 15911988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engraftment of human blood malignancies to the turkey embryo: a robust new in vivo model.
    Grinberg I; Reis A; Ohana A; Taizi M; Cipok M; Tavor S; Rund D; Deutsch VR; Goldstein RS
    Leuk Res; 2009 Oct; 33(10):1417-26. PubMed ID: 19297019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Combined Immunodeficient (SCID) Mice in Vaccine Assessment.
    Dennis MJ
    Methods Mol Med; 2003; 87():313-34. PubMed ID: 12958465
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac malignant lymphoma in severe combine immunodeficient mice.
    Aftabuddin M; Islam N; Alimuzzaman M; Koiralla TR; Hori Y
    Indian Heart J; 1996; 48(4):368-70. PubMed ID: 8908823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
    Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
    Vey N; Giles FJ; Kantarjian H; Smith TL; Beran M; Jeha S
    Clin Cancer Res; 2000 Feb; 6(2):731-6. PubMed ID: 10690560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
    Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
    Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo.
    Thomsen M; Yacoub-Youssef H; Marcheix B
    Tissue Antigens; 2005 Aug; 66(2):73-82. PubMed ID: 16029426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice.
    Weimar IS; Weijer K; van den Berk PC; Muller EJ; Miranda N; Bakker AQ; Heemskerk MH; Hekman A; de Gast GC; Gerritsen WR
    Br J Cancer; 1999 Sep; 81(1):43-53. PubMed ID: 10487611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid xenografts from patients with Graves' disease in severe combined immunodeficient mice and NIH-beige-nude-xid mice.
    Mukuta T; Arreaza G; Nishikawa M; Resetkova E; Jamieson C; Tamai H; Volpé R
    Clin Invest Med; 1997 Feb; 20(1):5-15. PubMed ID: 9013039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.